VOLITIONRX LTD (VNRX) Form 8-K — Aug 13, 2026
VolitionRx (NYSE American: VNRX) reported Q2 2026 results via an 8-K furnished August 13, 2026. Q2 revenue was approximately $0.4 million, in line with Q2 2025, while first-half revenue reached $1.4 million, up 112% year over year. Cost discipline is the standout: operating expenses fell 32% year over year under the company's cost reduction program, the Q2 operating loss narrowed 34% to $4.2 million, and operating cash burn declined 18% to $5.2 million. The quarter was funded in part by dilutive equity issuance — $1.2 million in net ATM proceeds plus $4.1 million in net proceeds from a confidentially marketed public offering of shares and warrants.
Key figures
- Revenue
- $0.4 million (Q2 2026, in line with Q2 2025)
- Revenue Yoy
- H1 2026 revenue +112% vs H1 2025; Q2 flat YoY
- H1 2026 revenue
- $1.4 million (+112% YoY)
- Cmpo proceeds q2 2026
- $4.1 million net from shares and warrants
- Operating loss q2 2026
- $4.2 million (down 34% YoY)
- Operating expense change
- -32% YoY in Q2 2026 (cost reduction program)
- Total addressable market
- more than $27 billion annualized across all product pillars
- Pending milestone payment
- $5 million tied to peer-reviewed publication of Nu.Q Vet feline lymphoma data
- Atm equity proceeds q2 2026
- $1.2 million net
- Net cash used in operating activities q2 2026
- $5.2 million (down 18% YoY)
Price after filing
Close on the filing date to close N calendar days later (from $0.63). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.